Avacta Group PLC PDMR Dealing and Issue of Equity (9751A)

TIDMAVCT

RNS Number : 9751A

Avacta Group PLC

04 January 2018

4 January 2018

Avacta Group plc

("Avacta", "the Group" or "the Company")

Issue of Equity

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that application has been made for 5,805 new ordinary shares of 10p each (the "New Ordinary Shares") to be admitted to trading on AIM on 11 January 2018 ("Admission").

The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, Non-Executive Director of the Company, of New Ordinary Shares in accordance with the terms set out in the Company's announcement of 23 February 2016.

Following Admission, the total number of ordinary shares with voting rights in issue will be 68,979,142. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0) 844 
  Alastair Smith, Chief Executive         414 0452 
  Officer                                 www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                             Tel: +44 (0) 207 
  Geoff Nash / Giles Rolls - Nominated    220 0500 
  Adviser                                 www.finncap.com 
  Tim Redfern / Alice Lane / Nikita 
  Jain - Corporate Broking 
                                          Tel: +44 (0) 203 
  WG Partners                             705 9318 
  Nigel Birks / Nigel Barnes              Tel: +44 (0) 203 
  David Wilson / Claes Spang              705 9217 
                                          www.wgpartners.co.uk 
 Zyme Communications (Trade and          Tel: [phone] 
  Regional Media)                         502 947 
  Katie Odgaard                           [e-mail] 
 
  Yellow Jersey PR (Financial             Tel: [phone] 
  Media and IR)                           947137 
  Sarah Hollins                           [e-mail] 
 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------------------------------------------------------------- 
 a)   Name                      Michael Albin 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 2.   Reason for the Notification 
---  --------------------------------------------------------------------------------------------------------------------- 
 a)   Position/status           Non - Executive Director 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 b)   Initial                    Initial notification 
      notification/Amendment 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 3.   Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------------------------------------------------------------- 
 a)   Name                      Avacta Group Plc 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 b)   LEI                       2138009U3EG31OPMGH36 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------------------------------------------------------------- 
 a)   Description of              Ordinary shares 
       the Financial                of 10p 
       instrument, type 
       of instrument 
--- 
      Identification            GB00BYYW9G87 
       code 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 b)   Nature of the               As set out in the Company's announcement of 23 February 2016, on 22 February 2016 Mr 
       transaction                 Albin 
                                   entered into a binding commitment to purchase new Avacta shares amounting to 50% of his 
                                   contractual 
                                   non-executive director fee per quarter and the New Ordinary Shares represent his 
                                   investment 
                                   for the period of 1 September 2017 to 31 December 2017. 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 c)   Price(s) and               Price(s)      Volume(s) 
       volume(s)                 ------------  ---------- 
                                  64.6 pence    5,805 
                                 ------------  ---------- 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 d)   Aggregated information: 
       *    Aggregated volume     See above 
 
 
       *    Price 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 e)   Date of the transaction   4 January 2018 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 f)   Place of the              London Stock Exchange, AIM 
       transaction               Market (XLON) 
---  ------------------------  ------------------------------------------------------------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEUGUWUGUPRGGC

(END) Dow Jones Newswires

January 04, 2018 06:04 ET (11:04 GMT)